Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Open access

Abstract

PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with immunofluorescence analysis, to uncover the immunogenomic determinants of the therapeutic response. Although conventional genomic markers (such as tumor mutation burden and neoantigen load) and the degree of CD8+ T cell infiltration were not associated with clinical response, we discovered numerous chromosomal alterations associated with response or resistance to PD-1 blockade. These advanced ccRCC tumors were highly CD8+ T cell infiltrated, with only 27% having a non-infiltrated phenotype. Our analysis revealed that infiltrated tumors are depleted of favorable PBRM1 mutations and enriched for unfavorable chromosomal losses of 9p21.3, as compared with non-infiltrated tumors, demonstrating how the potential interplay of immunophenotypes with somatic alterations impacts therapeutic efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-0839-y

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 85 · Cited by 992

Metadata

Authors
Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., Steinharter, J., Sun, M., Wind-Rotolo, M., Pignon, J.-C., Cherniack, A. D., Lichtenstein, L., Neuberg, D., Catalano, P., Freeman, G. J., Sharpe, A. H., McDermott, D. F., Van Allen, E. M., Signoretti, S., Wu, C. J., Shukla, S. A., & Choueiri, T. K.
Affiliations
  • Broad Institute (US)
  • Dana-Farber Cancer Institute (US)
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
  • Wu, Catherine J.
  • Shukla, Sachet A.
  • Choueiri, Toni K.
Venue
Nature Medicine
Published
2020-05-29
Volume
26
Issue
6
Pages
909-918
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3029490475
Cited by
992
References
85
Citations by year
2026: 119 · 2025: 148 · 2024: 209 · 2023: 189 · 2022: 205 · 2021: 105 · 2020: 17
FWCI
49.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P50CA101942, R50CA211482, R01CA155010, T32CA009172, U24CA224331)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
clear cell renal cell carcinoma, anti-PD-1 therapy, immune checkpoint inhibitors, CD8+ T cell infiltration, somatic alterations, chromosomal abnormalities, PBRM1 mutation, tumor mutational burden, neoantigens, immunogenomics, treatment response, immunotherapy resistance
MeSH terms
Exome Sequencing, Antineoplastic Agents, Immunological, Tuberous Sclerosis Complex 1 Protein, Nivolumab, Adult, Aged, Aged, 80 and over, Histocompatibility Antigens Class II, Carcinoma, Renal Cell, Chromosome Deletion, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 9, DNA-Binding Proteins, Female, Fluorescent Antibody Technique, Humans, Kidney Neoplasms, Male, Middle Aged, Mutation, Prognosis, Histone-Lysine N-Methyltransferase, Transcription Factors, Lymphocytes, Tumor-Infiltrating, Gene Deletion, Sequence Analysis, RNA, Antigen Presentation, CD8-Positive T-Lymphocytes, Genomics, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Proteasome Endopeptidase Complex, PTEN Phosphohydrolase, Von Hippel-Lindau Tumor Suppressor Protein, Histone Demethylases, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41591-020-0839-y
The paper
Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., Steinharter, J., Sun, M., Wind-Rotolo, M., Pignon, J.-C., Cherniack, A. D., Lichtenstein, L., Neuberg, D., Catalano, P., Freeman, G. J., . . . Choueiri, T. K. (2020). Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-020-0839-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.